{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:04:58Z","timestamp":1788206698574,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although angiotensin receptor-neprilysin inhibitor (ARNI) has shown promise in patients with heart failure and reduced ejection fraction (HFrEF), the treatment effect in HFrEF patients with end-stage renal disease (ESRD) undergoing dialysis is uncertain. This study aimed to examine the real-world effects of ARNI vs. angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEI\/ARB) in this subpopulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multi-institutional, retrospective study identified 349 HFrEF patients with ESRD on dialysis, who initiated either ARNI or ACEI\/ARB therapy. Efficacy outcomes included rates of hospitalization for heart failure (HHF) and mortality, as well as changes in echocardiographic parameters. Safety outcomes encompassed hypotension and hyperkalemia. Treatment effects were assessed using Cox proportional hazards models, with additional sensitivity analyses for robustness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 349 patients screened, 89 were included in the final analysis (42 in the ARNI group and 47 in the ACEI\/ARB group). After 1 year of treatment, echocardiographic measures between the two groups were comparable. The primary composite rate of HHF or mortality was 20.6 events per 100 patient-years in the ARNI group and 26.1 in the ACEI\/ARB group; the adjusted hazard ratio was 0.98 (95% CI: 0.28\u20133.43, <jats:italic>P<\/jats:italic>\u2009=\u20090.97). Their safety outcomes did not differ significantly. Sensitivity analyses, including repetitive sampling, propensity score matching, and extended follow-up, corroborated these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ARNI has proven effective in treating HFrEF patients; however, significant benefits were not observed in these patients with ESRD undergoing dialysis compared with ACEI\/ARB in this real-world cohort. Future research employing a more extended follow-up period, larger sample size, or randomized design is warranted to investigate the treatment effects in this subpopulation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1393440","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:49:05Z","timestamp":1721623745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world experience of angiotensin receptor-neprilysin inhibitors in patients with heart failure and dialysis"],"prefix":"10.3389","volume":"11","author":[{"given":"I-Ning","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Siong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Te","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","article-title":"Heart failure and liver disease: cardiohepatic interactions","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/nejm199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fcvm.2022.794707","article-title":"Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study","volume":"9","author":"Hsiao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mayocp.2022.06.007","article-title":"Real-world experience of angiotensin receptor-neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease","volume":"98","author":"Chang","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e026407","DOI":"10.1161\/jaha.122.026407","article-title":"Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease","volume":"11","author":"Niu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/kisup.2012.66","article-title":"Chapter 3: management of progression and complications of CKD","volume":"3","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"h2622","DOI":"10.1136\/bmj.h2622","article-title":"Statistics notes: bootstrap resampling methods","volume":"350","author":"Bland","year":"2015","journal-title":"BMJ Br Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/bsd.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/sj.ki.5000382","article-title":"The importance of residual renal function in dialysis patients","volume":"69","author":"Wang","year":"2006","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/ajkd.2001.25198","article-title":"Residual renal function and mortality risk in hemodialysis patients","volume":"38","author":"Shemin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1053\/j.ajkd.2009.02.012","article-title":"The importance of residual kidney function for patients on dialysis: a critical review","volume":"53","author":"Perl","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1053\/j.ajkd.2016.05.021","article-title":"Intensive hemodialysis and treatment complications and tolerability","volume":"68","author":"Morfin","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/antiox9111079","article-title":"Oxidative stress in ESRD patients on dialysis and the risk of cardiovascular diseases","volume":"9","author":"Rysz","year":"2020","journal-title":"Antioxidants"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1393440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:49:08Z","timestamp":1721623748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1393440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2024.1393440"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1393440","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1393440"}}